Pharmaceuticals Industry Trends United Kingdom - 2022

Market Monitor

  • United Kingdom
  • Chemicals/Pharma

15th March 2022

Large backlog of medical treatments to sustain growth in the coming years

IT UK pharma credit risk 2022

Pharmaceuticals value added output in the UK levelled off in 2021 after a strong 13.6% increase in 2020, which still leaves it 13% above the 2019 pre-pandemic level. The vaccination rollout and demand for pandemic-related drugs (e.g. medications to treat fever, drugs for intensive care) has driven growth, resulting in high profit margin increases for producers, and to a lesser extent for wholesalers and pharmacies. However, for some businesses border checks and regulatory burdens, due to Brexit, have raised costs and has delayed delivery of goods. Some businesses moved their operations to other European countries in order to retain easier market access in the EU.

IT UK pharma output 2022

There is still a large backlog of non-Covid related medical and elective care hospital treatments. The government and the NHS recently announced they would address this with a major catch-up programme over the next three years. This should sustain ongoing demand for pharmaceuticals.

Another growth driver in the mid- and long-term will be ageing of population. This will in particular spur demand for speciality drugs related to chronic diseases. However, despite higher public healthcare spending in the short-term, cost constraints will remain an issue in the long-term, and there will be pressure by the government and public health authorities on pharmaceutical businesses to lower sales costs of drugs. Rising imports of cheaper generics could be an outcome of cost pressures in the health system.

Payments in the industry take about 60 days on average, but longer payment terms imposed by the NHS are common. Payment behaviour has been very good over the past two years, and the number of both payment delays and insolvencies has been extraordinarily low in 2021.

With the expiry of large pandemic-related government support measures both payment delays and insolvencies could increase slightly year-on-year in 2022. However, this would only mean a reversion to the already low and stable levels seen in the years prior to the pandemic. Due to low credit risk, the robust demand situation and the financial strength of most businesses, our underwriting stance remains open across all segments.

 

 

 

 

 

Related documents

Disclaimer

Each publication available on or from our websites, such as, but not limited to webpages, reports, articles, publications, tips and helpful content, trading briefs, infographics, videos (each a “Publication”) is provided for information purposes only and is not intended as a recommendation or advice as to particular transactions, investments or strategies in any way to any reader. Readers must make their own independent decisions, commercial or otherwise, regarding the information provided. While we have made every attempt to ensure that the information contained in any Publication has been obtained from reliable sources, Atradius is not responsible for any errors or omissions, or for the results obtained from the use of this information. All information in any Publication is provided ’as is’, with no guarantee of completeness, accuracy, timeliness or of the results obtained from its use, and without warranty of any kind, express or implied. In no event will Atradius, its related partnerships or corporations, or the partners, agents or employees thereof, be liable to you or anyone else for any decision made or action taken in reliance on the information in any Publication, or for any loss of opportunity, loss of profit, loss of production, loss of business or indirect losses, special or similar damages of any kind, even if advised of the possibility of such losses or damages.